Viromed Medical AG, a medical technology company specializing in cold plasma technology, announced the successful completion of a multi-year study investigating the application of cold atmospheric plasma (CAP) in the lung. The study data will be submitted for publication in a peer-reviewed scientific journal. The research focused on ventilator-associated pneumonia (VAP), a critical challenge in intensive care medicine, and confirmed the potential of cold plasma as a physical, non-pharmacological treatment option for severe infectious lung diseases.
The results demonstrated a clearly defined therapeutic safety window and a complete reduction of pathogenic germs in lung epithelial models. An important component of the study was the ex vivo validation on vital lungs in collaboration with Saarland University and Hannover Medical School. The isolated, ventilation- and perfusion-capable lung model used realistically reflects key physiological characteristics of the human lung, enabling reproducible investigations on vital organ tissue.
Uwe Perbandt, Member of the Management Board of Viromed Medical AG, stated: “By successfully completing this study, we have reached a point of outstanding importance for Viromed and for modern pneumology. The data confirm the potential of our cold plasma technology in one of the most sensitive organ systems of the human body. It is particularly encouraging that we are no longer speaking only about preclinical evidence, but are already seeing first successful applications in patients in a university clinical setting.”
Based on the study results, Viromed’s technology has already been used in a university setting for a severe pulmonary individual case in a human patient. Following approval by the responsible ethics committee, a university hospital with a department specializing in lung and transplantation medicine treated a patient in connection with a lung transplant and massive complications. The use of cold plasma was very successful, and the treating physicians considered the observed positive clinical course exceptional. The hospital plans to publish the case in the near term, and further severely ill patients with a high risk of fatal outcome are undergoing treatment.
Viromed sees clear indications that cold plasma technology will fundamentally change pneumology. While classical pharmacological therapies are increasingly limited by the development of resistance, cold plasma as a physical mode of action opens up a new therapeutic dimension, particularly for the prevention of severe pulmonary infections. Looking ahead, further applications in intensive care medicine are moving into clinical research, such as intracardiac use in operations for bacterial endocarditis before implantation of a valve prosthesis, or application in the thorax for bacterial pleural empyema.
For more information about Viromed Medical AG and its cold plasma technology, visit www.viromed-medical-ag.de. The original press release is available at www.newmediawire.com.
